A clear-eyed guide for Mark Trance.
Don’t decide from fear of pharma or fear of procedures. Ask whether there is a clear culprit blockage causing the heart attack.
If yes — especially with STEMI, unstable/high-risk NSTEMI, ongoing ischemia, shock, dangerous rhythm, or a high-risk artery — the evidence leans toward angiography and PCI/stent if indicated.
If not — medical management or a second cardiology opinion may be reasonable.
Internist & Toxicologist · not a cardiology specialist
This isn’t my area of expertise, but stents are keeping people alive, and from everything I’ve read, it’s really the thing to do. It’s keeping a lot of people alive. If the muscle is broken down in the heart muscle, you’ve got to keep those arteries open so that you can rebuild the muscle and repair.
The clean comparison
Skeptical lens vs. evidence lens. The danger is ideology in either direction.
The anatomy of the choice
Troponin shows injury. The stent decision comes from ECG, symptoms, anatomy, stability, and whether opening the artery changes the outcome.
Troponin shows heart muscle injury, but the stent decision depends on ECG, symptoms, anatomy, and stability.
If there is a clearly blocked culprit artery — especially with STEMI, ongoing ischemia, shock, dangerous rhythm, or a high-risk lesion — the case for PCI/stent gets stronger.
If the case is lower-risk or unclear, medical management or a second opinion may be reasonable.
Evidence cards
Built for fast browsing: skeptical-but-not-reckless, scientific-but-not-cold.
For intermediate or high-risk NSTE-ACS, an invasive approach during hospitalization is recommended to reduce major adverse cardiovascular events. Default DAPT after ACS is at least 12 months unless bleeding risk is high.
Open sourceFor acute STEMI, NICE recommends coronary reperfusion as quickly as possible, with coronary angiography and follow-on primary PCI as preferred when indicated and time-feasible.
Open sourceFor unstable angina/NSTEMI, the review is nuanced: routine invasive strategies did not show appreciable mortality benefit overall, but did reduce MI, refractory angina, and rehospitalization in the reviewed follow-up window.
Open sourceIn stable ischemic heart disease, stents/surgery were not better than medication and lifestyle at reducing heart attack or death, though they helped symptoms and quality of life for some patients with angina.
Open sourceQuestions that cut through fear and fog
A good question is not resistance. It is intelligent consent.
Is this STEMI, NSTEMI, unstable angina, type 2 MI, or something else?
Is there a clearly identified culprit artery?
How blocked is it, and what is the blood flow?
Is he unstable: ongoing chest pain, ECG changes, heart failure, shock, or arrhythmia?
What benefit do you expect from a stent in this case?
What is the near-term risk if we choose medical management?
What exact antiplatelet plan would follow, and for how long?
What is the bleeding risk, and are there ways to reduce it?
The closing frame
Decide from anatomy and risk — not ideology.
Do not let fear of pharma make you allergic to lifesaving intervention. Do not let white coats turn uncertainty into inevitability either.
Sources
This brief is educational. Mark’s cardiology team owns the real recommendation because they have the ECG, angiogram, symptoms, vitals, labs, and bleeding risk.
This is not a diagnosis, prescription, or substitute for the treating cardiologist. A heart attack can be time-sensitive. If Mark has ongoing chest pain, shortness of breath, fainting, shock, rhythm instability, or worsening symptoms, the hospital team’s emergency pathway matters more than this brief.
